People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ribon Therapeutics, Inc. | — | Biotechnology | Series B | $119.1M | $343.2M | 2018 |
Marian M. Nakada at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marian M. Nakada on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Root | 1 | 16 |
| Cameron Wheeler | 1 | 9 |
| Jeff Goater | 1 | 4 |
| Paul Brannelly | 1 | 4 |
| Emma Reeve | 1 | 4 |
| Eyal Lifschitz | 1 | 3 |
| LAURA BRASS | 1 | 3 |
| Laurence Lasky | 1 | 2 |
| William M. Harrington | 1 | 2 |
| Gary Sutton | 1 | 2 |
| Emma M. Reeve | 1 | 1 |
| Jodie M. Morrison | 1 | 1 |
| Laura M. Brass | 1 | 1 |
| Anja M. Koenig | 1 | 1 |
| David M. Cordo | 1 | 1 |
| Jonathan M. Root | 1 | 1 |
| Victoria M. Richon | 1 | 1 |
| James Audia | 1 | 1 |
| Jodie Morrison | 1 | 1 |
| Prakash Raman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.